There is a growing demand for academic education for oncologists and haematologists to increase their clinical competence in the diagnosis and treatment of patients with haematological malignancies. Cancer is predicted to be an increasingly important cause of morbidity and mortality in the next few decades, in all regions of the world.
The expected demographic changes in the next two decades mean that even if current global cancer rates remain unchanged, the estimated incidence of 12.7 million new cancer cases in 2008 will rise to 21.4 million by 2030, with nearly two thirds of all cancer diagnoses occurring in low- and middle-income countries(1). Changing definitions and classifications of haematological malignancies (HMs) complicate incidence comparisons.
Nevertheless, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66.371 lymphoid malignancies (LMs) and 21.796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100.000) for LMs and 7.55 for MMs(2). The commonest LMs were plasma cell neoplasms (4.62), small B-cell lymphocytic lymphoma/chronic lymphatic leukaemia (3.79), diffuse B-cell lymphoma (3.13), and Hodgkin lymphoma (2.41). According to the epidemiological data, as well as the demographic trends, there is a growing, high demand for qualified and well educated oncologists treating patients with lymphoma.
At present numerous continuing medical education (CME) seminars in the field of lymphoma are offered. However, to our knowledge, this is the first competence programme which focuses on both the clinical and the scientific competence improving quality in the management of lymphoma patients.
The European School of Oncology, in co-operation with Ulm University, is pleased to present a structured Certificate of Competence in Lymphoma programme that was developed with the contribution of internationally recognised physicians and scientists in the field of haemato-oncology.
The curriculum was established observing the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines.
The programme, which is offered on a part-time basis over 14 months, is divided into three attendance seminars and four e-learning modules.
Upon successful completion of the programme, participants will obtain an academic certificate issued by the European School of Oncology and Ulm University assigning 14 European Credit Transfer and Accumulation System Points (ECTS), equalling a work load of 405 hours and a diploma supplement by Ulm University.
(1) Cancer incidence and mortality worldwide: Lyon, International Agency for Research on Cancer, 2011 (IARC CancerBase No.10).
(2) Sant M., Allemani C, Tereanu C et al.: Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010 116:3724-3734